Response to the center for medicare & medicaid services coverage with evidence development request for primary prevention implantable cardioverter-defibrillators: data from the omni study
Heart Rhythm, 07/11/2012
Sweeney MO et al. – Patient–year ventricular tachyarrhythmia therapy rates did not differ between non–Group B and Group B primary prevention (PP) implantable cardioverter–defibrillator (ICD) patients, though NDCM <9 months was significantly lower. Survival at 4 years was lowest in patients with New York Heart Association class IV HF treated with cardiac resynchronization therapy/defibrillator (CRT/D) and similar between all other non–Group B and Group B patients.
